Spots Global Cancer Trial Database for CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
Official Title: A Phase 1B/2A Trial Of CEND-1 In Combination With Neoadjuvant FOLFIRINOX Based Therapies In Pancreatic, Colon And Appendiceal Cancers (CENDIFOX)
Study ID: NCT05121038
Study Description
Brief Summary: This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
The University of Kansas Medical Center, North Kansas City, Missouri, United States
Contact Details
Name: Anup Kasi, MD
Affiliation: University of Kansas Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
